)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
aTyr Pharma (ATYR) investor relations material
aTyr Pharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Report covers the quarter ended September 30, 2025, for a clinical-stage biotech focused on tRNA synthetase biology for fibrosis and inflammation therapies.
Lead candidate efzofitimod is in late-stage development for interstitial lung disease (ILD), with recent Phase 3 results in pulmonary sarcoidosis; primary endpoint not met, but improvements seen in quality of life and steroid reduction.
The company is pre-commercial, with no product sales to date and ongoing R&D pipeline expansion.
Plans to meet with FDA in Q1 2026 to determine next steps for efzofitimod in pulmonary sarcoidosis.
Enrollment in Phase 2 EFZO-CONNECT study for systemic sclerosis-related ILD expected to complete in H1 2026.
Financial highlights
Cash, cash equivalents, restricted cash, and available-for-sale investments totaled $92.9 million as of September 30, 2025.
Net loss was $25.7 million for Q3 2025 and $60.2 million for the nine months ended September 30, 2025, compared to $17.3 million and $49.1 million for the same periods in 2024.
Revenue was $0.2 million for Q3 2025, from collaboration agreements, unchanged from Q3 2024.
R&D expenses increased to $22.1 million in Q3 2025, mainly for clinical trials and manufacturing.
General and administrative expenses rose to $4.8 million in Q3 2025, driven by personnel and pre-commercialization costs.
Outlook and guidance
Current cash and investments are expected to fund operations for at least one year from the filing date.
Additional capital will be needed for future development, regulatory, and commercialization activities.
The company plans to meet with the FDA in Q1 2026 to determine the regulatory path for efzofitimod in pulmonary sarcoidosis after the Phase 3 trial did not meet its primary endpoint.
Enrollment for the Phase 2 EFZO-CONNECT study in SSc-ILD is expected to complete in the first half of 2026.
EFZO-FIT primary endpoint miss: FDA path forward?
ATM offering viability given stock price volatility?
Preclinical pipeline progress: ATYR0101, ATYR0750?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next aTyr Pharma earnings date
Piper Sandler 37th Annual Healthcare Conference2 Dec, 2025
Next aTyr Pharma earnings date
Piper Sandler 37th Annual Healthcare Conference2 Dec, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
aTyr Pharma Inc. is a biotherapeutics company focused on the discovery and development of innovative medicines based on extracellular proteins to treat rare immune, inflammatory, and fibrotic diseases. The company's research is centered around the therapeutic potential of tRNA synthetase biology. aTyr's lead clinical program targets lung diseases with unmet medical needs, particularly those related to inflammation and fibrosis. The company aims to advance novel treatments that address the underlying causes of these conditions. The company is headquartered in San Diego, California, USA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage